Retatrutide (RT / LY3437943) 10 mg/vial — 10 Vials/Kit

Important: Retatrutide is still an investigational medicine as of September 2026 and is not FDA-approved for public use. Lilly describes it as a once-weekly investigational triple agonist targeting the GIP, GLP-1, and glucagon receptors. It is being evaluated in Phase 3 clinical trials for obesity, type 2 diabetes and several obesity-related conditions.

For an ecommerce product page, it is therefore more accurate and safer to present this product as a research/investigational peptide, rather than claiming it is an approved treatment or recommending that customers use it for self-treatment.

Product Identification

The identity information above is supported by PubChem records, which list retatrutide under the synonyms LY3437943 and LY-3437943 and identify CAS 2381089-83-2.

---

What Is Retatrutide?

Retatrutide, also known by the development code LY3437943, is an investigational peptide developed by Eli Lilly. It is notable because it is designed to activate three hormone receptors simultaneously: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor.

This three-receptor activity distinguishes retatrutide from single- and dual-receptor agonists. PubChem’s pharmacological information describes retatrutide as a triple peptidic agonist of GCGR, GIPR and GLP-1R.

Retatrutide is being investigated primarily in the area of metabolic health, including obesity and type 2 diabetes. Lilly’s current development pipeline also lists studies involving cardiovascular and renal outcomes, metabolic dysfunction-associated steatotic liver disease, knee osteoarthritis associated with obesity, obstructive sleep apnea and chronic low back pain.

The molecule is administered in clinical trials as a once-weekly subcutaneous injection, but the appropriate dose, administration schedule, safety profile and clinical indications remain matters for clinical research.

---

🔬 How Retatrutide Works

Retatrutide’s distinguishing characteristic is its triple receptor activity.

1. GIP receptor activity

GIP stands for glucose-dependent insulinotropic polypeptide. GIP is an incretin hormone involved in metabolic regulation.

Research into GIP receptor activation helps scientists understand how incretin signaling can influence glucose metabolism, energy balance and other physiological processes.

2. GLP-1 receptor activity

GLP-1, or glucagon-like peptide-1, is another important metabolic hormone.

GLP-1 receptor signaling has been extensively studied in relation to glucose regulation, appetite, gastrointestinal physiology and body-weight regulation.

3. Glucagon receptor activity

The third component is activation of the glucagon receptor.

Glucagon is involved in energy metabolism and glucose regulation. Retatrutide’s simultaneous activity at the glucagon receptor alongside GIP and GLP-1 receptors is one of the features researchers are investigating.

Together, these three pathways create the pharmacological concept behind retatrutide as a triple agonist.

---

🧪 Research Uses of Retatrutide

Retatrutide is being investigated across several areas.

⚖️ Obesity and body-weight research

One of the principal research applications is obesity and overweight.

In Lilly’s Phase 3 TRIUMPH-1 study, retatrutide was investigated in adults with obesity or overweight and at least one weight-related comorbidity. Lilly reported substantial reductions in body weight in the trial, although these results are investigational and do not mean the compound is approved for general use.

🩸 Type 2 diabetes research

Retatrutide is also being studied in people with type 2 diabetes.

Lilly’s 2026 Phase 3 reporting described improvements in HbA1c and body weight in the TRANSCEND-T2D-1 trial.

🦴 Osteoarthritis research

Researchers are also studying retatrutide in people with obesity or overweight and knee osteoarthritis.

A dedicated Phase 3 study evaluates retatrutide in this population, reflecting interest in whether weight reduction and metabolic effects may also affect obesity-associated complications.

😴 Obstructive sleep apnea research

Retatrutide is being investigated in people with obesity and moderate-to-severe obstructive sleep apnea. Lilly’s development program includes this indication as part of its Phase 3 research.

❤️ Cardiovascular research

Retatrutide is also being studied in participants with obesity and established cardiovascular disease.

The TRIUMPH-3 study was designed to evaluate the efficacy and safety of once-weekly retatrutide in this population.

🧬 Metabolic research

Additional research includes metabolic dysfunction-associated steatotic liver disease (MASLD) and other metabolic complications associated with excess weight.

---

⭐ Potential Advantages of Retatrutide for Research

The principal scientific interest in retatrutide comes from its multi-receptor mechanism.

These should be described as research advantages and investigated effects, rather than guaranteed benefits for individual customers.

---

📦 RT 10 mg/vial — 10 Vials/Kit

The RT 10 mg/vial, 10 vials/kit configuration represents a package containing ten individual vials, with each vial labeled as containing 10 mg of retatrutide.

Therefore:

10 mg × 10 vials = 100 mg total nominal peptide content per kit.

The packaging quantity itself should not be confused with a recommended clinical dose. The 10 mg/vial specification describes the quantity of material in each vial, while clinical dosing is a separate medical and regulatory matter.

For an ecommerce listing, you can present the packaging as:

10 mg per vial | 10 vials per kit | 100 mg total nominal content

---

🧪 Product Characteristics

Retatrutide is a peptide-based investigational compound. PubChem records identify retatrutide as LY3437943 and list CAS 2381089-83-2.

The compound is also described in pharmacological references as a peptide engineered for activity at three receptors.

For a professional product page, quality-related information such as purity, formulation, lyophilization status, analytical testing, batch number, certificate of analysis, storage conditions and manufacturer information should only be stated when they are actually supported by your supplier’s documentation.

Do not automatically claim “99% purity,” “GMP grade,” “sterile,” “pharmaceutical grade,” or “clinically proven” unless you possess documentation supporting those claims.

---

⚠️ Important Research and Regulatory Information

Retatrutide is not currently FDA-approved. Lilly states that it remains an investigational molecule and is available to participants through its clinical-trial programs rather than as an approved medicine for public use.

Consequently, a product page should avoid presenting RT 10 mg as an approved weight-loss medicine.

Avoid statements such as:

❌ “Guaranteed weight loss”
❌ “Approved weight-loss treatment”
❌ “Safe for everyone”
❌ “Use this injection to lose weight”
❌ “No side effects”
❌ “FDA approved”
❌ “Guaranteed diabetes treatment”

Instead, use scientifically accurate language such as:

✅ “Investigational peptide”
✅ “For research purposes”
✅ “Being studied in metabolic research”
✅ “Investigated as a GIP/GLP-1/glucagon triple agonist”
✅ “Not approved for general public use”

This distinction is particularly important because Lilly explicitly states that retatrutide’s safety and efficacy are still being evaluated.

---

📋 Detailed Product Information

---

🔍 Why Researchers Are Interested in Retatrutide

The major scientific interest is its ability to combine three distinct hormone-receptor pathways within a single molecule.

Traditional approaches may focus on one receptor pathway, while dual agonists combine two. Retatrutide is designed around three: GIP, GLP-1 and glucagon.

This makes it particularly valuable as a subject of research into the interaction between incretin signaling, glucagon signaling, energy metabolism, glucose regulation and body-weight regulation.

Clinical development has expanded beyond initial obesity research into type 2 diabetes, cardiovascular outcomes, osteoarthritis, sleep apnea and metabolic liver disease.

---

Retatrutide (LY3437943), also known as RT, is an investigational triple GIP/GLP-1/glucagon receptor agonist developed by Eli Lilly. This product configuration contains 10 vials, with 10 mg of retatrutide specified per vial, for a total nominal content of 100 mg per kit. Intended for research use and not approved for general public use.

Suggested Product Highlights

🧬 Retatrutide / LY3437943
🔬 Triple GIP/GLP-1/Glucagon receptor agonist
💊 10 mg per vial
📦 10 vials per kit
⚖️ 100 mg nominal total kit content
🧪 Investigational research compound
📚 Metabolic and cardiometabolic research applications
⚠️ Not FDA-approved for general public use

RT 10 mg/vial × 10 vials/kit is a 100 mg nominal-content research package of retatrutide (LY3437943). Its scientific importance comes from its triple agonist activity at the GIP, GLP-1 and glucagon receptors. Current research is examining its potential across obesity, type 2 diabetes and several related metabolic conditions, but it remains investigational rather than an approved medicine.